(Q45889315)

17 December 2017

title

Viral and non-viral gene therapy partially prevents experimental cisplatin-induced neuropathy (English)

1 reference

17 December 2017

0 references

Pradat PF

1

1 reference

17 December 2017

Kennel P

2

1 reference

17 December 2017

Naimi-Sadaoui S

3

1 reference

17 December 2017

Finiels F

4

1 reference

17 December 2017

Scherman D

5

1 reference

17 December 2017

Orsini C

6

1 reference

17 December 2017

Delaere P

7

1 reference

17 December 2017

Mallet J

8

1 reference

17 December 2017

Revah F

9

1 reference

17 December 2017

publication date

1 October 2002

1 reference

17 December 2017

published in

Gene Therapy

1 reference

17 December 2017

volume

9

1 reference

17 December 2017

issue

19

1 reference

17 December 2017

page(s)

1333-1337

1 reference

17 December 2017

Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301801

The neurotrophins BDNF, NT-3, and NGF display distinct patterns of retrograde axonal transport in peripheral and central neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301801

Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301801

Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301801

Partial prevention of cisplatin-induced neuropathy by electroporation-mediated nonviral gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301801

Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301801

Continuous delivery of neurotrophin 3 by gene therapy has a neuroprotective effect in experimental models of diabetic and acrylamide neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301801

In vivo gene therapy for pyridoxine-induced neuropathy by herpes simplex virus-mediated gene transfer of neurotrophin-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301801

Peripheral neuropathies and neurotrophic factors: animal models and clinical perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301801

Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301801

Gene transfer into muscle by electroporation in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301801

Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301801

Nerve growth factor administration protects against experimental diabetic sensory neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301801

Therapeutic applications of neurotrophic factors in disorders of motor neurons and peripheral nerves

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301801

Herpesvirus-mediated systemic delivery of nerve growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301801

Improvement in chronic ischemic neuropathy after intramuscular phVEGF165 gene transfer in patients with critical limb ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301801

Recombinational construction in Escherichia coli of infectious adenoviral genomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301801

Neurotrophin‐3 reverses experimental cisplatin‐induced peripheral sensory neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301801

7 January 2021

Neurotrophin-3 administration attenuates deficits of pyridoxine-induced large-fiber sensory neuropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301801

7 January 2021

Expression of neurotrophins and their receptors in sciatic nerve of experimentally diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301801

7 January 2021

Decreased neurotrophin-3 expression in skeletal muscles of streptozotocin-induced diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301801

7 January 2021

Physiological and immunohistochemical characterization of cisplatin-induced neuropathy in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301801

7 January 2021

Continuous erythropoietin delivery by muscle-targeted gene transfer using in vivo electroporation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301801

7 January 2021

Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3301801

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3301801

1 reference

17 December 2017

Dimensions Publication ID

1032107661

0 references

1 reference

17 December 2017